FORM DEF 14A
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment No. )
Filed by the Registrant þ
Filed by a Party other than the Registrant o
Check the appropriate box:
o |
|
Preliminary Proxy Statement |
|
o |
|
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
þ |
|
Definitive Proxy Statement |
|
o |
|
Definitive Additional Materials |
|
o |
|
Soliciting Material Pursuant to §240.14a-12 |
Synergetics USA, Inc.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
þ |
|
No fee required. |
|
o |
|
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. |
|
(1) |
|
Title of each class of securities to which transaction applies: |
|
|
|
|
|
|
|
(2) |
|
Aggregate number of securities to which transaction applies: |
|
|
|
|
|
|
|
(3) |
|
Per unit price or other underlying value of transaction computed pursuant to Exchange Act
Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was
determined): |
|
|
|
|
|
|
|
(4) |
|
Proposed maximum aggregate value of transaction: |
|
|
|
|
|
|
|
(5) |
|
Total fee paid: |
|
|
|
|
|
o |
|
Fee paid previously with preliminary materials. |
|
o |
|
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and
identify the filing for which the offsetting fee was paid previously. Identify the previous filing
by registration statement number, or the Form or Schedule and the date of its filing. |
|
(1) |
|
Amount Previously Paid: |
|
|
|
|
|
|
|
(2) |
|
Form, Schedule or Registration Statement No.: |
|
|
|
|
|
|
|
(3) |
|
Filing Party: |
|
|
|
|
|
|
|
(4) |
|
Date Filed: |
|
|
|
|
|
|
|
|
Persons who are to respond to the collection of information contained in this form are not
required to respond unless the form displays a currently valid OMB control number. |
SYNERGETICS
USA, INC.
3845 Corporate Centre Drive
OFallon, Missouri 63368
November 17,
2008
Dear Stockholder:
You are cordially invited to attend our Companys 2008
Annual Meeting of Stockholders, which will be held on
December 11, 2008, at 6:00 p.m. Central Time at The
Doubletree Hotel and Conference Center located at
16625 Swingley Ridge Road, Chesterfield, Missouri 63017.
The formal Notice of Annual Meeting of Stockholders and Proxy
Statement accompanying this letter describe the business to be
acted upon at the meeting.
Your vote is important to us and your shares should be
represented at the meeting whether or not you are personally
able to attend. Accordingly, I encourage you to mark, sign, date
and return the accompanying proxy promptly.
On behalf of the Board of Directors, thank you for your
continued support of Synergetics USA, Inc.
Sincerely,
Pamela G. Boone
Executive Vice President, Chief Financial Officer,
Treasurer and Secretary
SYNERGETICS
USA, INC.
NOTICE OF ANNUAL MEETING OF
STOCKHOLDERS
To Be Held On December 11,
2008
NOTICE IS HEREBY GIVEN that the 2008 Annual Meeting of
Stockholders of Synergetics USA, Inc., a Delaware corporation
(the Company), will be held on December 11,
2008, at 6:00 p.m. Central Time at The Doubletree Hotel and
Conference Center located at 16625 Swingley Ridge Road,
Chesterfield, Missouri 63017 to act upon the following matters,
which are described more fully in the accompanying Proxy
Statement:
1. The election of two directors nominated by the
Companys Nominating and Governance Committee to serve
three year terms following approval by the stockholders at the
Annual Meeting;
2. The approval of Amendment No. 1 to the Amended and
Restated Synergetics USA, Inc. 2005 Non-Employee Directors
Stock Option Plan to increase the number of shares authorized
for issuance under the plan from 200,000 to 400,000;
3. The ratification of the appointment of the
Companys independent registered public accounting firm for
fiscal 2009, UHY LLP (UHY); and
4. Such other business as may properly come before the
meeting
and/or any
adjournment or postponement thereof.
All holders of Common Stock of record at the close of business
on November 10, 2008 are entitled to notice of, and to vote
at, the Annual Meeting or any adjournment or postponement
thereof.
The Board of Directors of the Company has authorized the
solicitation of proxies. Unless otherwise directed, the proxies
will be voted FOR the election of the nominees listed in the
attached Proxy Statement to be members of the Board of Directors
of the Company, FOR the approval of Amendment No. 1
to the Amended and Restated Synergetics USA, Inc. 2005
Non-Employee Directors Stock Option Plan, FOR ratification
of UHYs appointment and on other business that may
properly come before the Annual Meeting, as the named proxies in
their best judgment shall decide.
Any stockholder submitting a proxy may revoke such proxy at any
time prior to its exercise by notifying the Secretary of the
Company in writing at 3845 Corporate Centre Drive,
OFallon, Missouri, 63368 prior to the Annual Meeting, and,
if you attend the Annual Meeting, you may revoke your proxy if
previously submitted and vote in person by notifying the
Secretary of the Company at the Annual Meeting.
This Notice of Annual Meeting and the Proxy Statement and the
form of proxy are being distributed on or about
November 17, 2008.
Your vote is very important. Whether or not you plan to attend
the Annual Meeting, we encourage you to read the Proxy Statement
and submit your proxy as soon as possible. You may submit your
proxy for the Annual Meeting by completing, signing, dating and
returning your proxy in the pre-addressed envelope provided.
By Order of the Board of Directors,
PAMELA G. BOONE, Secretary
OFallon, Missouri
November 17, 2008
TABLE OF CONTENTS
SYNERGETICS
USA, INC.
PROXY
STATEMENT
FOR THE
2008 ANNUAL MEETING OF STOCKHOLDERS
GENERAL
INFORMATION
This Proxy Statement is being furnished in connection with the
solicitation of proxies by the Board of Directors of Synergetics
USA, Inc., a Delaware corporation (the Company),
3845 Corporate Centre Drive, OFallon, Missouri, 63368, for
use at the 2008 Annual Meeting of Stockholders to be held on
December 11, 2008, at 6:00 p.m. Central Time at The
Doubletree Hotel and Conference Center located at 16625 Swingley
Ridge Road, Chesterfield, Missouri 63017. The Board of Directors
of the Company urges you to promptly execute and return your
proxy in the enclosed envelope, even if you plan on attending
the Annual Meeting. This is designed to authenticate
stockholders identities, to allow stockholders to give
their voting instructions and to confirm that stockholders
instructions have been recorded properly.
Any stockholder submitting a proxy may revoke such proxy at any
time prior to its exercise by notifying the Secretary of the
Company, in writing, prior to the Annual Meeting. Any
stockholder attending the Annual Meeting may revoke his or her
proxy and vote personally by notifying the Secretary of the
Company at the Annual Meeting. Only stockholders of record at
the close of business on November 10, 2008, will be
entitled to notice of, and to vote at, the Annual Meeting or any
adjournment or postponement thereof. At the close of business on
November 10, 2008, the Company had 24,354,295 outstanding
shares of Common Stock, $0.001 par value per share (the
Common Stock). Each share of Common Stock entitles
the holder thereof to one vote.
If the accompanying proxy card is signed and returned, the
shares represented thereby will be voted in accordance with the
directions on the proxy card. Unless a stockholder specifies
otherwise therein, the proxy will be voted in accordance with
the recommendations of the Board of Directors on all proposals.
The presence in person or by proxy of a majority of the voting
power represented by outstanding shares of Common Stock will
constitute a quorum for the transaction of business at the
Annual Meeting.
Directors will be elected by a plurality of the voting power
represented and entitled to vote at the meeting. The passage of
any other proposal will be determined by the affirmative vote of
the majority of the voting power represented and entitled to
vote at the meeting. In the election of directors, abstentions
and broker non-votes will not affect the outcome except in
determining the presence of a quorum; they will not be counted
toward the number of votes required for any nominees
election. An instruction to abstain from voting on
any other proposal will have the same effect as a vote against
the proposal. Broker non-votes will not be considered as present
and entitled to vote on the proposals; therefore, broker
non-votes will have no effect on the number of affirmative votes
required to adopt such proposal.
This Proxy Statement and the enclosed proxy card are being
mailed to the stockholders of the Company on or about
November 17, 2008.
PROPOSAL 1
ELECTION OF DIRECTORS
The Companys Amended and Restated Bylaws provide that the
Board shall consist of not less than five nor more than 11
members, the exact number of which shall be determined by the
Board. The number of directors on the Companys Board of
Directors is currently set at seven directors, divided into
three classes with each class serving three-year staggered terms.
Effective July 31, 2008, Gregg D. Scheller resigned as the
Companys President, Chief Executive Officer and Chairman
of the Board. Under the Companys Amended and Restated
Certificate of Incorporation and Amended and Restated Bylaws,
the Board has the authority to fill the vacancy caused by
Mr. Schellers resignation by a
majority vote of the directors then in office, even if less than
a quorum. The Nominating and Corporate Governance Committee of
the Board has not made an appointment as of the date of this
proxy statement. Therefore, the Companys Board currently
consists of six directors and contains one vacancy.
Mr. Schellers term as director would have expired at
the 2008 Annual Meeting, but for his earlier resignation. The
Companys Nominating and Corporate Governance Committee has
not identified a qualified candidate for nomination for election
as a director to fill the vacancy caused by
Mr. Schellers resignation, and the Company has not
received any additional proper nominations from stockholders.
Therefore, only two nominees stand for election to the Board at
the 2008 Annual Meeting, as discussed below. The Board intends
to appoint a successor to Mr. Scheller pursuant to its
authority under the Amended and Restated Certificate of
Incorporation and Amended and Restated Bylaws. Pursuant to the
terms of the Amended and Restated Certificate of Incorporation,
when appointed, Mr. Schellers successor will have the
same remaining term as that of his or her predecessor.
Therefore, Mr. Schellers successor will serve until
the annual election of directors in 2011, or until his or her
successor is duly elected and qualified, or his or her earlier
death, resignation or removal. Proxies cannot be voted for a
greater number of persons than the number of nominees named.
The terms of Kurt W. Gampp, Jr. and Jerry L. Malis also
expire at the 2008 Annual Meeting. Messrs. Gampp and Malis
have been nominated for re-election. The Board of Directors of
the Company recommends a vote FOR the two nominees. If
re-elected, each nominee will serve until the annual election of
directors in the year 2011 or until his successor is duly
elected and qualified, or his earlier death, resignation or
removal. If any of the nominees are unavailable for election, an
event which the Board of Directors of the Company does not
presently anticipate, the persons named in the enclosed proxy
intend to vote the proxies solicited hereby FOR the election of
such other nominee or nominees as may be nominated by the Board
of Directors.
Based on the recommendation of the Nominating and Corporate
Governance Committee, both of the nominees have been approved
unanimously by the Board of Directors of the Company for
re-election. Set forth below is information concerning the two
nominees for director and the directors whose terms are
continuing.
Nominees
for Directors to be Re-Elected at the 2008 Annual Meeting for
Terms expiring in 2011
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Expiration
|
Name
|
|
Age
|
|
Principal Occupation and Other Information
|
|
of Term
|
|
Kurt W. Gampp, Jr.
|
|
|
48
|
|
|
Kurt W. Gampp, Jr. is the Companys Executive Vice
President and Chief Operating Officer and has served in these
positions and as a director since 2005 when Synergetics, Inc.
merged with Valley Forge Scientific Corp. (Valley
Forge) (now known as Synergetics USA, Inc. or the
Company). Immediately prior to the merger with
Valley Forge, Mr. Gampp served as the Executive Vice President
and Chief Operating Officer of Synergetics, Inc. and had served
in this position since Synergetics, Inc. was founded in 1991.
Mr. Gampp coordinates and supervises the manufacturing of
the Companys products and is in charge of the daily
production operations of the Company.
|
|
|
2011
|
|
Jerry L. Malis
|
|
|
75
|
|
|
Jerry L. Malis is the Companys Executive Vice President
and Chief Scientific Officer and has served in these positions
and as a director since 2005. Immediately prior to the
consummation of the merger with Valley Forge, Dr. Malis
served as Valley Forges Chief Executive Officer, President
and Chairman of the Board of Valley Forge. He has published
over 50 articles in the biological science, electronics and
engineering fields, and has been issued ten United States
patents. Dr. Malis coordinates and supervises the
scientific developments of the Company.
|
|
|
2011
|
|
2
Directors
whose Terms Continue beyond the 2008 Annual Meeting
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Expiration
|
Name
|
|
Age
|
|
Principal Occupation and Other Information
|
|
of Term
|
|
Lawrence C. Cardinale
|
|
|
70
|
|
|
Lawrence C. Cardinale has served as a director of the Company
since 2005. Mr. Cardinale received his B.S.B.A. in Business
from Washington University in St. Louis, Missouri and has
recently retired after working in the medical industry since
1966. During his over 35 years working in the field of
medical manufacturing, he held various management positions,
including Plant Manager, Director of Manufacturing, Director of
Corporate Engineering, Director of Operations Planning, Vice
President of Manufacturing-International and Vice
President-Global Manufacturing and Engineering of a
multi-national medical manufacturing company. Mr. Cardinale
also owned and operated a scientific laboratory instrument
business concentrating in the life sciences area, which
manufactured and marketed tissue sectioning, microforge and
micromanipulation instruments and pipeting devices. Mr.
Cardinale formerly served as a board member of
Coretech-Holdings
LLC, a St. Louis-based life sciences and medical device
manufacturing company, and McCormick Scientific, LLC.
|
|
|
2010
|
|
Guy R. Guarch
|
|
|
67
|
|
|
Guy R. Guarch has been a director of the Company since 2005,
when Synergetics, Inc. merged with Valley Forge. Mr. Guarch
retired in 2001 from C.R. Bard, Inc. where he spent
32 years in various sales, marketing and management roles.
Bard is a leading developer, manufacturer and marketer of health
care products used for vascular, urological and onocological
diagnosis and intervention. From 1993 to 2001, Mr. Guarch served
as Regional Vice President Corporate Account Manager for
Bards Southeast Region. He worked as President of Bard
Venture Division in Boston, Massachusetts from 1991 to 1993.
From 1988 to 1991, Mr. Guarch worked in London, England, as Vice
President of Sales for the Bard European Division and Managing
Director of Bard LTD, UK. Before 1988, Mr. Guarch worked in
several sales and marketing roles for Bards USCI
International Division in Boston, Massachusetts, which focused
on the design, manufacture and sale of cardiac catheters,
urological catheters and artificial arteries. Mr. Guarch
currently serves as a board member and chairman of the
governance committee for Span-America Medical Systems, Inc.,
which designs and manufactures wound management products and
which has securities registered pursuant to Section 12 of the
Securities Exchange Act of 1934 (the Exchange Act).
|
|
|
2010
|
|
3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Expiration
|
Name
|
|
Age
|
|
Principal Occupation and Other Information
|
|
of Term
|
|
Robert H. Dick
|
|
|
64
|
|
|
Robert H. Dick has been a director of the Company since 2005,
when Synergetics, Inc. merged with Valley Forge, and currently
serves as the Chairman of the Board of Directors. He has served
as Chairman of the Board of Directors since July 31, 2008.
Prior to the merger, Mr. Dick had been a director of Valley
Forge since 1997. Mr. Dick has served as President of R.H. Dick
& Company since January 1998, a consulting firm based in
Camp Verde, Texas. From 1996 to 1998, he was a partner with
Boles, Knop & Company, Inc., an investment banking firm in
Middleburg, Virginia. From 1994 to 1996, Mr. Dick served as
interim President, Chief Executive Officer and Chief Financial
Officer of two of Boles clients. From 1982 until 1994, he
served in various executive roles with Codman & Shurtleff,
Inc., a subsidiary of Johnson & Johnson and a manufacturer
of surgical instruments, implants, equipment and other surgical
products. From 1978 to 1982, Mr. Dick was President and Chief
Executive Officer of Applied Fiberoptics, Inc., a company
designing, manufacturing and marketing fiberoptic products for
medical and defense applications, and surgical microscopes for
microsurgery. From 1969 to 1978, Mr. Dick held various sales,
marketing and general management positions with the USCI
division of C.R. Bard, Inc. Mr. Dick also serves as a member of
the board, chairman of the audit committee and member of the
executive and governance committees for
Span-America
Medical Systems, Inc., which designs and manufactures wound
management products and which has securities registered pursuant
to Section 12 of the Exchange Act.
|
|
|
2009
|
|
Juanita H. Hinshaw
|
|
|
63
|
|
|
Juanita H. Hinshaw has served as a director of the Company since
2005 when Synergetics, Inc. merged with Valley Forge. Ms.
Hinshaw has been President and Chief Executive Officer of
H&H Advisors (a financial advisory company) since 2005. In
addition, Ms. Hinshaw served as Senior Vice President and Chief
Financial Officer of Graybar Electric Company from May 2000 to
May 2005. Graybar Electric Company specializes in supply chain
management services and distributes high-quality components,
equipment and materials for the electrical and
telecommunications industries. Ms. Hinshaw has served as a
director, chairman of the finance committee and as a member of
the audit committee for The Williams Companies, Inc. since 2004
and has served as a director on the board, chairman of the
compensation committee and as a member of the audit committee
for Insituform Technologies, Inc. since 1999. The Williams
Company and Insituform Technologies, Inc. have securities
registered pursuant to Section 12 of the Exchange Act.
|
|
|
2009
|
|
CORPORATE
GOVERNANCE
The Companys Board of Directors met six times during the
fiscal year ended July 31, 2008, two of which were special
meetings. Each of our directors attended at least 75% of all the
meetings of the Board and those committees on which he or she
served during fiscal year 2008 either in person or
telephonically. The Board of Directors encourages all members to
attend stockholder meetings, but has not adopted a formal policy
regarding attendance. All of the Companys directors
attended last years annual stockholders meeting.
4
The Board of Directors has determined that each of the directors
other than Messrs. Gampp and Malis satisfies the definition
of an independent director set forth in the listing standards of
The NASDAQ Stock Market, Inc. (Nasdaq) and the
Companys Corporate Governance Guidelines, available on the
Companys website at www.synergeticsusa.com. In
addition, the Board of Directors has determined that each of the
members of the Audit Committee satisfies the additional
conditions for independence for Audit Committee members required
by Nasdaq.
The Board is in process of hiring a successor to
Mr. Scheller to serve as Chief Executive Officer. Until his
successor is appointed, Messrs. Cardinale, Dick and Guarch
and Ms. Hinshaw each visit the Company on a weekly rotating
basis to provide general oversight of the Companys
operations. These directors are also compensated for their
services as discussed in the section Director
Compensation below. The Board has considered this
arrangement in light of the applicable Nasdaq rules, the
Companys Corporate Governance Guidelines and applicable
rules of the Securities and Exchange Commission
(SEC) and has concluded that Messrs. Cardinale,
Dick and Guarch and Ms. Hinshaw meet the definitions and
other conditions for independence promulgated by these rules.
The Companys Corporate Governance Guidelines also state
that the independent directors should meet each time that a
regularly scheduled Board meeting is held, in addition to
holding other meetings as needed. During fiscal 2008, the
independent directors held eight meetings of which four were in
conjunction with regularly scheduled Board meetings and four
were special meetings.
The Board of Directors maintains three standing committees,
including an Audit Committee, a Compensation Committee and a
Nominating and Corporate Governance Committee. Each of these
committees operates pursuant to a written charter setting forth
the functions and responsibilities of the committee, which may
be reviewed on our website at www.synergeticsusa.com and
are also available to stockholders in print upon request.
Audit
Committee
The Audit Committee is responsible for the appointment,
evaluation, compensation and oversight of the work of the
independent registered public accounting firm and, where
appropriate, the dismissal of the independent registered public
accounting firm. Furthermore, the Audit Committee is responsible
for meeting with the independent registered public accounting
firm and other corporate officers to review matters relating to
financial reporting and accounting procedures and policies.
Among other responsibilities, the Audit Committee also reviews
financial information provided to stockholders and others,
assesses the adequacy of financial, accounting, operating and
disclosure controls, evaluates the scope of the audits of the
independent registered public accounting firm and internal
auditors, and reports on the results of such audits to the Board
of Directors. The current members of the Audit Committee are
Ms. Hinshaw (Chairperson), Mr. Dick, and
Mr. Cardinale, all of whom meet all applicable standards
for Audit Committee membership under the Nasdaq listing
standards and SEC rules. The Board of Directors has determined
that Ms. Hinshaw qualifies as an audit committee financial
expert because she has served in oversight roles in finance and
accounting. The Audit Committee held five meetings during the
last fiscal year.
Compensation
Committee
The Compensation Committee is composed entirely of independent
directors, as defined by The Nasdaq Stock Market listing
standards and SEC rules, and is responsible for administering
the Companys compensation programs and recommending to the
Board of Directors other compensation and benefits of the Chief
Executive Officer and all named executive officers. The current
members of the Compensation Committee are Mr. Dick
(Chairperson), Mr. Cardinale and Mr. Guarch. The
Compensation Committee held four meetings during the last fiscal
year.
The Compensation Committee meets at the end of each fiscal year
to determine and recommend to the Board for approval the
compensation packages for executive officers in light of the
Companys compensation philosophy and objectives as
presented in the Compensation Discussion and
Analysis below. Until July 31, 2008, the Compensation
Committee considered recommendations from the Chief Executive
Officer as to compensation for each executive officer based upon
their performance against Company and personal objectives, other
than himself.
5
The Compensation Committee has full responsibility to recommend
to the independent directors of the Board the compensation
package of the Chief Executive Officer.
Nominating
and Corporate Governance Committee
The members of the Companys Nominating and Corporate
Governance Committee are Mr. Cardinale (Chairperson),
Mr. Dick and Mr. Guarch, all of whom meet the
independence requirements of The Nasdaq Stock Market listing
standards and SEC rules. The Nominating and Corporate Governance
Committee is responsible for identifying individuals qualified
to become members of the Board of Directors, recommending to the
Board of Directors the director nominees to be proposed for
election by the stockholders and recommending to the Board of
Directors corporate governance guidelines and procedures
applicable to the Company. The Nominating and Corporate
Governance Committee held four meetings during the last fiscal
year.
The Nominating and Corporate Governance Committee will consider
director nominees recommended by stockholders of the Company.
Each stockholder must comply with applicable requirements of the
Companys Amended and Restated Bylaws and the Exchange Act
with respect to the nomination of, or proposal of, nominees for
election as directors of the Company. Stockholders should submit
any such nominations, together with appropriate biographical
information and a description of the nominees
qualifications to serve as director, to the Chairperson of the
Nominating and Corporate Governance Committee,
c/o Pamela
G. Boone, Secretary, Synergetics USA, Inc., 3845 Corporate
Centre Drive, OFallon, Missouri 63368. As stated in the
Companys Governance Guidelines, the Nominating and
Corporate Governance Committee has established general
qualifications for director nominees that it recommends to the
Board of Directors. These guidelines require that the candidate
for the position of independent director be able to demonstrate:
(i) independence as defined above, (ii) integrity,
(iii) leadership ability, (iv) sound judgement,
(v) prior experience operating at policy-making levels,
preferably in a public company, and (vi) experience in the
medical device field, preferably in the Companys field of
microsurgery, or related medical fields. Final approval of a
candidate is determined by the full Board of Directors. Nominees
to be evaluated by the Nominating and Corporate Governance
Committee for future vacancies on the Board of Directors will be
selected by the Committee from candidates recommended by
multiple sources, including members of the Board of Directors,
senior management, independent search firms, stockholders and
other sources, all of whom will be evaluated based on the same
criteria.
Code of
Conduct and Ethics
The Company has established a Code of Business Conduct and
Ethics, which is applicable to all of its employees, officers
and directors. The Code is available on the Companys
website at www.synergeticsusa.com and also available to
stockholders in print upon request. We intend to post any future
amendments and revisions to the Code of Business Conduct and
Ethics on our website.
COMPENSATION
COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION
As of July 31, 2008, the members of the Compensation
Committee for Synergetics USA, Inc. were Mr. Robert H.
Dick (Chairperson), Mr. Lawrence C. Cardinale and
Mr. Guy R. Guarch.
No member of the Compensation Committee of the Company during
fiscal 2008 was an employee or officer of the Company or any of
its subsidiaries. During the year ended July 31, 2008, no
executive officer of the Company served as a member of
(i) the compensation committee of another entity for which
one of the executive officers of such entity served on the
Companys Compensation Committee, (ii) the Board of
Directors of another entity for which one of the executive
officers of such entity served on the Companys
Compensation Committee, or (iii) the compensation committee
of another entity for which one of the executive officers of
such entity served as a member of the Companys Board of
Directors.
6
COMMUNICATIONS
WITH THE BOARD OF DIRECTORS
Stockholders may communicate directly with the Board of
Directors, as a group, or any individual director by submitting
written correspondence addressed to the Board or an individual
director at Synergetics USA, Inc., 3845 Corporate Centre
Drive, OFallon, Missouri 63368.
DIRECTOR
COMPENSATION
Directors who are neither employees of the Company nor an
immediate family member of an officer of the Company are paid
$750 for each meeting of the Board of Directors and each meeting
of a committee of the Board of Directors that they attend. The
Chairperson of the Audit Committee receives $2,250 for each
meeting of the Audit Committee. In addition, all directors are
entitled to reimbursement for travel and lodging expenses
incurred in connection with their attendance at meetings.
Compensation for members of the Board has been established and
will be reviewed annually by the Compensation Committee. The
Compensation Committee may not delegate its authority regarding
director compensation, and no executive officer plays a role in
determining the amount of director compensation. The
Compensation Committee considers the amount of time directors
dedicate to Company matters and the need to attract and retain
qualified directors when determining Board compensation. For
example, the Compensation Committee has approved additional
compensation for the Audit Committee Chairperson in recognition
of the time commitment required by such position.
To align the interests of directors with those of the
Companys stockholders, each independent director also
receives an option to purchase 10,000 shares of the
Companys Common Stock each year in which he or she is
elected, appointed, or re-elected to serve as a director
pursuant to the Amended and Restated 2005 Non-Employee
Directors Stock Option Plan, which is discussed in more
detail under PROPOSAL 2 APPROVAL OF
AMENDMENT NO. 1 TO THE AMENDED AND RESTATED 2005
NON-EMPLOYEE DIRECTORS STOCK OPTION PLAN below.
As noted above, Mr. Scheller resigned as the Companys
President, Chief Executive Officer and Chairman of the Board,
effective July 31, 2008. Subsequently, the Board appointed
Mr. Dick to serve as the Chairman of the Board. Until a
successor to Mr. Scheller is hired, each of the independent
directors visits the Company on a weekly rotating basis, as
discussed in the section CORPORATE GOVERNANCE above.
The independent directors are compensated for these services and
receive at the standard Board meeting rate of $750 per day for
each day spent at the Company and each day spent away from
personal business on Company business. In addition, the
independent directors receive $500 per meeting for each meeting
of the independent directors. This compensation arrangement has
been approved by the management directors.
The following table discloses compensation paid for the fiscal
year ended July 31, 2008 to the directors for serving as
members of the Board. Directors who are also employees of the
Company do not receive compensation for their services as
members of the Board of Directors. Therefore, there is no
director compensation to report for Messers. Gampp, Malis and
Scheller during the fiscal year ended July 31, 2008.
2008 Director
Compensation
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fees Earned
|
|
|
|
|
|
|
|
|
|
or Paid in
|
|
|
|
|
|
|
|
|
|
Cash
|
|
|
Option
|
|
|
Total
|
|
Name
|
|
($)
|
|
|
Awards ($)(1)(2)
|
|
|
($)
|
|
|
Lawrence C. Cardinale
|
|
$
|
16,750
|
|
|
$
|
24,500
|
|
|
$
|
41,250
|
|
Robert H. Dick
|
|
$
|
16,750
|
|
|
$
|
24,500
|
|
|
$
|
41,250
|
|
Guy R. Guarch
|
|
$
|
13,750
|
|
|
$
|
24,500
|
|
|
$
|
38,250
|
|
Juanita H. Hinshaw
|
|
$
|
17,500
|
|
|
$
|
24,500
|
|
|
$
|
42,000
|
|
7
|
|
|
(1) |
|
The fair value of each of the options granted to the independent
directors during the fiscal year ended July 31, 2008 was
determined at the date of the grant using a Black-Scholes
options-pricing model and the following assumptions: |
|
|
|
|
|
Expected average risk-free interest rate*
|
|
|
3.5
|
%
|
Expected average life (in years)
|
|
|
5.0
|
|
Expected volatility
|
|
|
69.2
|
%
|
Expected dividend yield
|
|
|
0.0
|
%
|
|
|
|
* |
|
As of the date of the last grant (December 7, 2007) |
|
|
|
|
|
The fair value of each of the options granted to the independent
directors on the date of the grant was $2.45, the exercise price
is $2.95 and the options vest pro-rata over twelve months from
the grant date. The options expire ten years from the date of
grant. |
|
(2) |
|
The table below shows the aggregate outstanding number of
options as of the fiscal year ended July 31, 2008 and their
respective status: |
|
|
|
|
|
|
|
|
|
|
|
|
|
Name
|
|
Vested
|
|
|
Unvested
|
|
|
Total
|
|
|
Lawrence C. Cardinale
|
|
|
26,667
|
|
|
|
3,333
|
|
|
|
30,000
|
|
Robert H. Dick
|
|
|
86,667
|
|
|
|
3,333
|
|
|
|
90,000
|
|
Guy R. Guarch
|
|
|
26,667
|
|
|
|
3,333
|
|
|
|
30,000
|
|
Juanita H. Hinshaw
|
|
|
26,667
|
|
|
|
3,333
|
|
|
|
30,000
|
|
PRINCIPAL
STOCKHOLDERS
The following table sets forth as of November 10, 2008
certain information with respect to the beneficial ownership of
the Companys Common Stock by (i) each of the named
executive officers and directors, (ii) all executive
officers and directors as a group, and (iii) each person
known by the Company to beneficially own more than 5% of the
Companys Common Stock based on certain filings made under
Section 13 of the Exchange Act. All such information
provided by the stockholders who are not executive officers or
directors reflects their beneficial ownership as of the dates
specified in the footnotes to the table. The percent of shares
beneficially owned is based on 24,354,295 shares issued and
outstanding as of November 10, 2008.
|
|
|
|
|
|
|
|
|
|
|
Amount and
|
|
|
Percent of
|
|
|
|
Nature of
|
|
|
Shares
|
|
|
|
Beneficial
|
|
|
Beneficially
|
|
Name and Address of Beneficial Owner
|
|
Ownership
|
|
|
Owned
|
|
|
(i) Named Executive Officers and Directors(1)
|
|
|
|
|
|
|
|
|
Gregg D. Scheller(2)
|
|
|
824,373
|
(3)
|
|
|
3.4
|
%
|
Lawrence C. Cardinale
|
|
|
54,244
|
(4)
|
|
|
*
|
|
Robert H. Dick
|
|
|
93,000
|
(5)
|
|
|
*
|
|
Kurt W. Gampp, Jr.
|
|
|
869,842
|
(6)
|
|
|
3.6
|
%
|
Guy R. Guarch
|
|
|
34,000
|
(7)
|
|
|
*
|
|
Juanita H. Hinshaw
|
|
|
356,710
|
(8)
|
|
|
1.5
|
%
|
Jerry L. Malis
|
|
|
1,114,745
|
(9)
|
|
|
4.6
|
%
|
Pamela G. Boone
|
|
|
87,700
|
(10)
|
|
|
*
|
|
Dave Dallam
|
|
|
5,792
|
(11)
|
|
|
*
|
|
(ii) All Executive Officers and Directors as a Group
(8 persons)
|
|
|
2,616,033
|
|
|
|
10.7
|
%
|
(iii) Certain Beneficial Owners
|
|
|
|
|
|
|
|
|
JPMorgan Chase & Co.
|
|
|
1,896,701
|
(12)
|
|
|
7.8
|
%
|
Louis Uchitel
|
|
|
1,460,975
|
(13)
|
|
|
6.1
|
%
|
8
|
|
|
(1) |
|
Except as indicated in the footnotes to this table, the persons
named in the table have sole voting and investment power with
respect to all shares of Common Stock shown as beneficially
owned by them. |
|
(2) |
|
Mr. Scheller resigned as the Companys President,
Chief Executive Officer and Chairman of the Board of Directors,
effective July 31, 2008. |
|
(3) |
|
The data reported for Mr. Scheller includes
809,373 shares held by Mr. Scheller. Mr. Scheller
possesses sole voting and investment power with respect to these
shares. Also includes 15,000 shares issuable to
Mr. Scheller subject to options currently exercisable.
Mr. Scheller has until July 31, 2010 to exercise these
options. This does not include 817,020 shares held by the
Donna Scheller Trust, of which Mr. Schellers wife is
trustee. Mr. Scheller disclaims beneficial ownership as to
these shares. |
|
(4) |
|
Includes 30,000 shares issuable to Mr. Cardinale
subject to options exercisable currently or within 60 days. |
|
(5) |
|
Includes 90,000 shares issuable to Mr. Dick subject to
options exercisable currently or within 60 days. |
|
(6) |
|
Includes shares held in the Kurt W. Gampp, Jr. Trust. This does
not include 116,725 shares held by the Julie Gampp Trust,
of which Mr. Gampps wife is trustee, nor
64 shares held by his daughter, Lindsey Gampp.
Mr. Gampp disclaims beneficial ownership as to these shares. |
|
(7) |
|
Includes 30,000 shares issuable to Mr. Guarch subject
to options exercisable currently or within 60 days. |
|
(8) |
|
Includes shares held in the Hinshaw-Harrison Joint Revocable
Living Trust. Ms. Hinshaw, in her capacity as trustee,
possesses joint voting and investment power with respect to
these shares. Also includes 30,000 shares issuable to
Ms. Hinshaw subject to options exercisable currently or
within 60 days. |
|
(9) |
|
Includes 50,000 shares issuable to Dr. Malis subject
to options exercisable currently or within 60 days. Also
includes 200,000 shares held in the Malis Family L.P., a
limited partnership in which Jerry L. Malis is the general
partner and possesses voting and investment power. |
|
(10) |
|
Includes the following: 32,700 shares issued to
Ms. Boone subject to restrictions, including a cliff
vesting period of five years from the date of the grant:
6,387 shares in March, 2006, 11,050 shares in August,
2007 and 15,263 shares in August, 2008. |
|
(11) |
|
Includes 5,792 shares issued to Mr. Dallam subject to
restrictions, including a cliff vesting period of five years
from the date of the grant in January, 2008. This does not
include 9,600 shares held by Rocio Munoz,
Mr. Dallams wife. Mr. Dallam disclaims
beneficial ownership as to these shares. |
|
(12) |
|
Pursuant to JPMorgan Chase & Co.s
Schedule 13G/A filed with the SEC on January 29, 2008.
JPMorgan Chase & Co. has sole voting and dispositive
power with respect to 1,896,701 shares. The address of
JPMorgan Chase & Co. is 270 Park Avenue, New York, NY
10017. |
|
(13) |
|
Pursuant to Mr. Uchitels Schedule 13D/A filed
with the SEC October 27, 2008, Mr. Uchitel has sole
voting power over 185,327 shares, shared voting power over
518,100 shares, sole dispositive power over
185,327 shares and shared dispositive power over
1,275,648 shares. Mr. Uchitels address is 142
Cedar Road, Elkins Park, PA 19027. |
SECTION 16(a)
BENEFICIAL OWNERSHIP REPORTING COMPLIANCE
Section 16(a) of the Exchange Act requires the
Companys directors and executive officers, and persons who
own more than 10% of a registered class of the Companys
equity securities, to file reports of ownership of, and
transactions in, the Companys securities with the SEC and
Nasdaq. Such directors, executive officers and 10% stockholders
are also required to furnish the Company with copies of all
Section 16(a) forms they file.
Based solely upon a review of reports furnished to the Company,
and on written representations from certain reporting persons,
the Company believes that, with respect to the fiscal year ended
July 31, 2008, each director, executive officer and 10%
stockholder of the Companys securities made timely filings
of all reports required by Section 16 of the Exchange Act,
except as follows: Mr. Cardinale filed a late Form 4
on January 31, 2008 reporting his stock purchase.
Mr. Dallam filed a late Form 4 on November 5,
2008 reporting his grant of restricted stock options on
January 31, 2008.
9
EXECUTIVE
OFFICERS OF THE REGISTRANT
The following table sets forth certain information, as of the
date of this proxy statement, with respect to the executive
officers of the Company.
|
|
|
|
|
|
|
Name
|
|
Age
|
|
Position(s) with the Company
|
|
Kurt W. Gampp, Jr.
|
|
|
48
|
|
|
Executive Vice President, Chief Operating Officer & Director
|
Jerry L. Malis
|
|
|
75
|
|
|
Executive Vice President, Chief Scientific Officer &
Director
|
Pamela G. Boone
|
|
|
45
|
|
|
Executive Vice President, Chief Financial Officer, Treasurer
& Secretary
|
Dave Dallam
|
|
|
56
|
|
|
Executive Vice President of Sales & Marketing
|
The biographical information for Messrs. Gampp and Malis
can be found under Proposal 1 Election of
Directors above.
Ms. Boone joined the Company as its Chief Financial Officer
in May 2005. Prior to this, Ms. Boone served as Vice
President and Chief Financial Officer of Maverick Tube
Corporation from 2001 until January 2005 and as Vice President,
Treasurer and acting Chief Financial Officer until May 2005.
Maverick Tube Corporation, a Missouri-based company, was a
leading North American producer of welded tubular steel products
used in energy and industrial applications. From 1997 to 2001,
Ms. Boone served as Mavericks Corporate Controller.
Mr. Dallam joined the Company as its Executive Vice
President of Sales and Marketing in November 2007. Prior to
this, Mr. Dallam served as Vice President and North
American General Manager for Leica Microsystems, a producer of
surgical microscopes for both ophthalmic and neurosurgical
applications, since 1996. In addition, he has held executive
positions with Carl Zeiss, Inc. and Storz Instrument Company,
now the surgical division of Bausch & Lomb
Incorporated.
EXECUTIVE
COMPENSATION
Compensation
Discussion and Analysis
The following Compensation Discussion and Analysis describes the
material elements of compensation for our named executive
officers.
Executive
Compensation Philosophy and Objectives
The Compensation Committee believes that compensation paid to
our named executive officers should accomplish the following
objectives:
|
|
|
|
|
Reflect the accomplishment of corporate and individual
objectives, and
|
|
|
|
Assist the Company in attracting, motivating and retaining
superior talent.
|
Our compensation program is intended to motivate our named
executive officers to achieve our business objectives and to
align their financial interests with those of our stockholders.
These objectives are furthered by a compensation philosophy that
is based on the following:
|
|
|
|
|
Accountability and Recognition for Individual and Corporate
Performance: Compensation should depend, in part,
on the Companys overall performance and on each executive
officers performance in order to motivate and reward
success. The Compensation Committee has provided for a portion
of the overall compensation packages to be tied to performance
through the payments of annual incentive awards in the form of
cash bonuses and the grant of long-term incentive awards in the
form of stock options and restricted stock.
|
|
|
|
Competition with the Market: Base salaries
should generally be competitive with officers with similar
positions at companies within our industry and market, subject
to individual adjustments as discussed below.
|
10
Compensation
Determination Process
Our Compensation Committee is responsible for establishing,
implementing and monitoring our executive compensation program.
The Compensation Committee consists of Messrs. Dick,
Cardinale and Guarch, each of whom is an independent director.
The Compensation Committee typically meets following each fiscal
year end to (i) consider and approve salary changes and
annual incentive bonuses, if any; (ii) determine and
approve long-term incentive awards, if any; and
(iii) establish goals for the annual incentive program.
In making its determinations regarding compensation, the
Compensation Committee evaluates corporate performance and each
executive officers individual performance. In addition,
although the Company does not engage in any formal benchmarking,
the Compensation Committee does review compensation data from
the following companies (collectively, the Peer
Companies):
|
|
|
|
|
Alphatec Holdings, Inc. is a medical technology company focused
on the design, development, manufacturing and marketing of
products for the surgical treatment of spine disorders, with
approximately $80 million in annual revenue as reported in
the December 31, 2007
Form 10-K.
|
|
|
|
Bovie Medical Corporation is actively engaged in the business of
manufacturing and marketing medical products related to
electrosurgery and developing related technologies and has
approximately $29 million in annual revenue as reported in
the December 31, 2007
Form 10-K.
|
|
|
|
Iridex Corporation is a leading worldwide provider of
therapeutic based laser systems and delivery devices used to
treat eye diseases in ophthalmology and skin conditions in
dermatology with approximately $56 million in annual
revenue as reported in the December 29, 2007
Form 10-K.
|
|
|
|
Orthovita, Inc. is a spine and orthopedic biosurgery company
with proprietary biomaterials and biologic technologies for the
development and commercialization of synthetic, biologically
active, tissue engineering products with approximately
$58 million in annual revenue as reported in the
December 31, 2007
Form 10-K.
|
|
|
|
SenoRx, Inc. develops, manufactures and sells minimally-invasive
medical devices that are used in the diagnosis of breast cancer
and has approximately $35 million in annual revenue as
reported in the December 31, 2007
Form 10-K.
|
|
|
|
StereoTaxis, Inc., a St. Louis-based company, designs,
manufactures and markets an advanced cardiology instrument
control system for use in a hospitals interventional
surgical suite and has approximately $30 million in annual
revenue as reported in the December 31, 2007
Form 10-K.
|
|
|
|
Thermage, Inc. designs, develops, manufactures and markets
medical devices for the non-invasive treatment of wrinkles and
has approximately $63 million in annual revenue as reported
in the December 31, 2007
Form 10-K.
|
|
|
|
Vascular Solutions, Inc. is a medical device company focused on
bringing clinically advanced solutions to interventional
cardiologists and interventional radiologists worldwide with
approximately $53 million in annual revenue as reported in
the December 31, 2007
Form 10-K.
|
The Compensation Committee reviews the executive officer
compensation packages of the Peer Companies in connection with
its executive officer compensation determinations. Although the
Compensation Committee does not formally benchmark against the
Peer Companies, or target a median or other point for the
executive officer compensation packages, it does utilize the
Peer Companies compensation data for purposes of setting
executive officer compensation.
The mix of the Companys cash and non-cash compensation and
short- and long-term compensation is not subject to a specific
policy. Instead, the Compensation Committee considers the Peer
Companies compensation data in light of the Companys
compensation philosophies and objectives outlined above, as well
as corporate and individual performance, and makes gradual
changes over time as necessary to further these compensation
goals. The methodology provides for the Chief Executive Officer
to make recommendations to the Compensation Committee regarding
proposed salary changes, bonuses and equity compensation awards,
if any, for each executive officer other than himself. The Chief
Executive Officer also participates in the setting of Company
performance
11
goals on which part of each officers total compensation is
based. The Compensation Committee considers these
recommendations from the Chief Executive Officer, as well as
other factors it believed are relevant, and determines the
compensation packages of the executive officers, including the
Chief Executive Officer. Because the Companys Chief
Executive Officer resigned on July 31, 2008, the
Compensation Committee determined fiscal 2009 compensation with
no recommendations from a named executive officer, based on the
factors described herein.
Elements
of Compensation
Base Salary. The base salaries of each of
Messrs. Scheller, Gampp and Malis and Ms. Boone in
fiscal 2008 are reflected in the Summary Compensation Table and
were established pursuant to employment terms negotiated with
each of these officers at the time of the merger of Synergetics,
Inc. and Valley Forge, before the current Compensation Committee
of the Board of Directors of the Company had been formed. The
employment agreements with Messrs. Scheller, Gampp and
Malis were entered into in September 2005 in anticipation of the
completion of the merger and provided for minimum base salaries
of $377,000, $346,000 and $230,000, respectively.
Messrs. Gampps and Malis employment agreements
expired on September 21, 2008 according to their terms. The
negative covenants provisions in these agreements survive. Base
salary changes for Messrs. Gampp and Malis for fiscal 2008
were based upon their accomplishments and the analysis of the
range of salaries for the named executive officers as they
relate to the Peer Companies.
Ms. Boone joined the Company in May 2005, and her
employment terms provided for a minimum base salary of $175,000.
Ms. Boones 2008 salary was increased to $232,000
pursuant to the then Chief Executive Officers
recommendations and approved by the Compensation Committee based
upon her accomplishments during the year and the range of
salaries for the Chief Financial Officers of the Peer Companies.
For fiscal 2009, the Compensation Committee reviewed and
recommended to the full Board of Directors base salary increases
for each of the named executive officers. These salary increases
were based on the Companys desires that base salaries
remain competitive to attract, retain and motivate named
executive officers as well as reward performance.
When evaluating competitiveness, the Compensation Committee
evaluates the salaries of officers with similar positions at the
Peer Companies. As noted above, in reviewing comparative data,
the Compensation Committee does not engage in benchmarking for
the purpose of establishing salary levels relative to any
predetermined point. In the Compensation Committees view,
this external data provides insight into competitiveness, but is
not an appropriate single factor in determining base salaries.
Rather, the Compensation Committee, as noted above, takes into
account overall performance of the named executive officers and
the Company.
As noted above, the Compensation Committee bases salary
decisions on a combination of Company and individual performance
and peer company salary ranges. Company performance is based on
the achievement of the Companys goals as set forth in its
annual financial plan, which is discussed in further detail
below. The Compensation Committee establishes specific
individual performance objectives for purposes of determining
salary increases, but bases its decisions on its evaluation of
(i) each named executive officers general performance
over the prior fiscal year, taking into consideration the
accomplishment scores each receive, as more fully described
below; (ii) the scope of each officers duties and
responsibilities; (iii) each officers experience and
expertise; and (iv) the peer range data for similar
positions. In the past, the Compensation Committee sought input
from Mr. Scheller in evaluating the named executive
officers other than himself.
Based on the factors discussed above, the Compensation Committee
increased the base salaries for the named executive officers for
fiscal 2009 as illustrated in the table below:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Percentile in
|
|
|
Fiscal 2009
|
|
|
|
|
|
|
|
|
|
2007 Peer
|
|
|
2007 Peer
|
|
|
Percentage
|
|
|
|
|
|
|
Fiscal 2008
|
|
|
Group
|
|
|
Group
|
|
|
Salary
|
|
|
Fiscal 2009
|
|
Name
|
|
Salary
|
|
|
Range
|
|
|
Range
|
|
|
Increase
|
|
|
Salary
|
|
|
Kurt W. Gampp, Jr.
|
|
$
|
359,840
|
|
|
$
|
166,000 to $341,000
|
|
|
|
105
|
%
|
|
|
1
|
%*
|
|
$
|
363,437
|
|
Jerry L. Malis
|
|
$
|
240,240
|
|
|
$
|
195,000 to $294,000
|
|
|
|
82
|
%
|
|
|
5
|
%
|
|
$
|
252,252
|
|
Pamela G. Boone
|
|
$
|
232,000
|
|
|
$
|
94,000 to $309,000
|
|
|
|
75
|
%
|
|
|
5
|
%
|
|
$
|
243,600
|
|
Dave Dallam
|
|
$
|
215,000
|
|
|
$
|
195,000 to $294,000
|
|
|
|
82
|
%
|
|
|
4
|
%
|
|
$
|
223,600
|
|
12
|
|
|
* |
|
The increase of 1% reflects Mr. Gampps current salary
as compared to the Peer Companies comparison and is not an
indication of Mr. Gampps performance during fiscal
2008. |
Bonus Compensation. Prior to fiscal 2007,
bonuses to executive officers were discretionary, based on the
Compensation Committees evaluation of each executive
officers individual performance and the Companys
overall performance. Determinations regarding bonuses were based
on qualitative criteria, including the achievement of sales
forecasts and successful transition after Synergetics,
Inc.s merger with Valley Forge and compliance with public
company reporting requirements. The Compensation Committee and
Company management believes the establishment of clear
objectives with periodic measurement of results is an effective
method for focusing resources, communicating mission and
strategy for the period, and in determining the individual named
executive officers contribution to the achievement of
Company goals. Accordingly, beginning in fiscal 2007, the
Company implemented a method for establishing clear, measurable
objectives for the named executive officers, divided into two
categories:
|
|
|
|
|
Company-wide objectives, and
|
|
|
|
Functional and personal development objectives.
|
The objectives of each category are a function of the
individuals responsibilities and span of control. For the
named executive officers, Company-wide objectives are weighed
more heavily than functional and personal development objectives
in evaluating performance. The Compensation Committee is
involved in the establishment and approval of the Company-wide
objectives, as well as functional and personal objectives for
the executive officers and, in the past, sought the
recommendations of the Chief Executive Officer in determining
these objectives for named executive officers other than
himself. Since Mr. Schellers resignation, the Chief
Financial Officer assists the Compensation Committee in
determining Company-wide financial objectives.
Original Company-wide objectives established for fiscal 2008
include for the named executive officers the achievement of the
following goals:
|
|
|
|
|
Sales Forecast of approximately $54 million
|
|
|
|
Gross Profit Margin of approximately $32 million
|
|
|
|
Operating Income of approximately $6 million
|
|
|
|
Earnings per Share of $0.14
|
These goals are set at aggressive levels each year to motivate
the named executive officers to succeed and focus on both short-
and long-term Company objectives. Target goals are designed to
be challenging and as such, the Committee believes that the
Companys target performance would not be achieved all of
the time, but that the payout relating to these goals should be
appropriate for the performance, regardless of how often target
levels are reached.
In addition, each named executive officer has both functional
and personal developmental goals which include projects within
their functional areas of the Company and individual growth
goals.
13
Accomplishments at the end of the period are compared to
objectives set at the beginning of the period with
scoring of each objective relative to 100%
accomplishment of the objective. The scores for each category
are then averaged, and the average score is translated to a
percentage of base salary in accordance with the following scale:
|
|
|
|
|
|
|
|
|
|
|
Percent of Base Salary
|
|
Average Accomplishment Score
|
|
Chief Executive Officer*
|
|
|
Other Named Executives
|
|
|
91%
|
|
|
2
|
%
|
|
|
1
|
%
|
92%
|
|
|
3
|
%
|
|
|
2
|
%
|
93%
|
|
|
5
|
%
|
|
|
3
|
%
|
94%
|
|
|
6
|
%
|
|
|
4
|
%
|
95%
|
|
|
8
|
%
|
|
|
5
|
%
|
96%
|
|
|
10
|
%
|
|
|
7
|
%
|
97%
|
|
|
11
|
%
|
|
|
7
|
%
|
98%
|
|
|
13
|
%
|
|
|
8
|
%
|
99%
|
|
|
14
|
%
|
|
|
9
|
%
|
100%
|
|
|
16
|
%
|
|
|
10
|
%
|
101%
|
|
|
18
|
%
|
|
|
11
|
%
|
102%
|
|
|
19
|
%
|
|
|
12
|
%
|
103%
|
|
|
21
|
%
|
|
|
13
|
%
|
104%
|
|
|
22
|
%
|
|
|
14
|
%
|
105%
|
|
|
24
|
%
|
|
|
15
|
%
|
106-115%
|
|
|
32
|
%
|
|
|
20
|
%
|
116-125%
|
|
|
40
|
%
|
|
|
25
|
%
|
126-130%
|
|
|
48
|
%
|
|
|
30
|
%
|
|
|
|
* |
|
Standard Percentage plus 60% rounded up to the next percentile. |
For the named executive officers, the accomplishment scores are
also considered generally in compensation decisions for base
salary adjustments and equity award grants, if any.
The Compensation Committee has made its determinations regarding
executive officer incentive bonuses for the fiscal year ended
July 31, 2008, as disclosed in the Summary Compensation
Table. The executive officers received bonuses based upon their
percentage of objectives achieved in the Company-wide objectives
and the functional and personal development objectives. Though
the Company fell slightly short in meeting certain Company-wide
financial objectives, each of the continuing named executive
officers largely met his or her functional and personal
development objectives, resulting in the bonuses disclosed in
the Summary Compensation Table. In addition to the incentive
bonuses awarded, each executive officer was awarded a $5,000
non-incentive, non-discretionary holiday bonus during fiscal
2008, with the exception of Mr. Dallam who received a $500
non-incentive, non-discretionary holiday bonus. These holiday
bonuses are reflected in the Summary Compensation Table.
Equity Awards. Equity compensation is
currently not a major component of the Companys executive
compensation program. Rather, the Compensation Committee grants
equity-based compensation pursuant to established employment
terms, in the case of Ms. Boone and Mr. Dallam, or for
exceptional performance based upon the scores discussed above.
The Compensation Committee does not intend to grant any equity
awards based on fiscal 2008 performance. The Compensation
Committee did award Mr. Dallam 5,792 shares of
restricted stock in January 2008 pursuant to the terms of his
letter agreement and did award Ms. Boone 15,263 shares
of restricted stock in August 2008 pursuant to the terms of her
employment agreement.
Mr. Dallams and Ms. Boones restricted
Common Stock was granted under our 2001 Plan. Furthermore, any
equity awards, if any, to be made based on fiscal 2008
performance will be made under the 2001 Plan. Pursuant to the
2001 Plan, employees, including our executive officers, of, and
consultants and advisors to, our Company and its subsidiaries
are eligible to receive awards of incentive and non-statutory
stock options, restricted stock and
14
unrestricted Common Stock. While the Compensation Committee
considers the recommendations of management, the Compensation
Committee has the exclusive authority and sole discretion to
administer the 2001 Plan, including the power to determine
eligibility, the types and sizes of awards, the price and timing
of awards and the acceleration or waiver of any vesting
restriction, subject to the limitations set forth in the 2001
Plan.
Pursuant to the terms of the 2001 Plan, stock options with
respect to no more than 100,000 shares of Common Stock may
be granted to any individual participant during any one calendar
year period. Options granted pursuant to the 2001 Plan are
subject to the terms of the option agreement related to the
specific grant; provided, however, that (i) the term
of any incentive stock option granted to a non-10% stockholder
of the Company pursuant to the 2001 Plan may be no more than
10 years from the date of grant, and (ii) the term of
any incentive stock option granted to a 10% stockholder of the
Company pursuant to the 2001 Plan may be no more than five years
from the date of grant.
Incentive stock options must be granted at no less than the fair
market value of the Companys Common Stock on the grant
date; provided, however, that incentive stock options
granted to 10% stockholders must be granted at no less than 110%
of such fair market value. Non-statutory stock options must be
granted at no less than 85% of the fair market value of the
Companys Common Stock on the date of grant.
Generally, to the extent that an optionees employment with
the Company is terminated other than for cause, the optionee
may, but only within 90 days (or such other period of time
as determined by the Board of Directors) after such date of
termination, but in no event later than the expiration date of
the option as set forth in the respective option agreement,
exercise his or her options to the extent the optionee was
entitled to exercise the option at the date of termination.
Pursuant to the terms of the 2001 Plan, restricted stock awards
may also be granted. Restricted stock awards are subject to such
restrictions and conditions as the Compensation Committee
determines. Such conditions may be based on continuing
employment
and/or
achievement of pre-established performance goals and objectives.
If the recipient violates any of the restrictions during the
period specified by the committee or the performance standards
fail to be satisfied, the restricted stock is forfeited.
Other Employment Benefits. Synergetics
named executive officers are provided with a limited number of
perquisites. In fiscal 2008, the Company provided an automobile
allowance with respect to Dr. Malis, but it was less than
$10,000 in the aggregate for fiscal 2008.
Severance and Other Post-Termination
Benefits. During fiscal 2008,
Messrs. Scheller, Gampp and Malis each had an employment
agreement with the Company. These employment agreements provided
for certain payments upon termination, depending on the
circumstances of termination. Messrs. Gampps and
Malis employment agreements expired on September 21,
2008 according to their terms. The negative covenants provisions
in these agreements survive. As such, neither Mr. Gampp nor
Dr. Malis have agreements with the Company providing for
severance payments or post-termination benefits.
Ms. Boones employment agreement with the Company is
still in effect and also provides for certain payments upon
termination of her employment, depending on the circumstances.
Ms. Boones agreement and Mr. Dallams
letter agreement also provide for certain payments to be made to
each of them upon a change of control. Furthermore, if any of
the named executive officers employment is terminated upon
a change of control, all options to purchase Common Stock and
all restricted stock shall vest. These provisions are discussed
later in this proxy statement.
Impact
of Tax Treatments of Executive Compensation
Section 162(m) of the Internal Revenue Code of 1986, as
amended, provides that compensation in excess of $1,000,000 paid
to the Chief Executive Officer or to any of the other four most
highly compensated executive officers of a publicly held
corporation will not be deductible for federal income tax
purposes unless such compensation is paid pursuant to one of the
enumerated exceptions set forth in Section 162(m). In
general, stock options granted under our 2001 Equity Incentive
Plan are intended to qualify under and comply with the
performance based compensation exemption provided
under Section 162(m), thus excluding from the
Section 162(m) compensation limitation any income
recognized by executives pursuant to such stock options. In
fiscal 2007, no executive officer received compensation that
triggered the applicability of Section 162(m). The
15
Compensation Committee intends to review periodically the
potential impacts of Section 162(m) in structuring and
administering our compensation programs.
Compensation
Committee Report
The Companys Compensation Committee has reviewed and
discussed the Compensation Discussion and Analysis with
management and, based on such review and discussions, the
Compensation Committee recommended to the Companys Board
of Directors that the Compensation Discussion and Analysis be
included in this Proxy Statement on Schedule 14A and
incorporated by reference in the Companys Annual Report on
Form 10-K
for the fiscal year ended July 31, 2008.
Submitted by the Compensation Committee of
the Board of Directors.
Robert H. Dick (Chairperson)
Lawrence C. Cardinale
Guy R. Guarch
2008
Summary Compensation Table
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
All
|
|
|
|
|
Fiscal
|
|
|
|
|
|
Stock
|
|
Option
|
|
Other
|
|
|
Name and Principal Position
|
|
Year
|
|
Salary
|
|
Bonus
|
|
Awards
|
|
Awards
|
|
Compensation
|
|
Total
|
|
Gregg D. Scheller(1)
|
|
|
2008
|
|
|
$
|
395,850
|
|
|
$
|
5,000
|
(9)
|
|
|
|
|
|
$
|
29,403
|
(2)
|
|
|
|
|
|
$
|
430,253
|
|
|
|
|
2007
|
|
|
$
|
377,000
|
|
|
$
|
5,000
|
|
|
|
|
|
|
$
|
14,850
|
(2)
|
|
|
|
|
|
$
|
396,850
|
|
Kurt W. Gampp, Jr.
|
|
|
2008
|
|
|
$
|
359,840
|
|
|
$
|
15,795
|
(9)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
375,635
|
|
Executive Vice
|
|
|
2007
|
|
|
$
|
346,000
|
|
|
$
|
5,000
|
|
|
|
|
|
|
|
|
|
|
$
|
23,248
|
(6)
|
|
$
|
374,248
|
|
President & Chief Operating Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Jerry L. Malis
|
|
|
2008
|
|
|
$
|
240,240
|
|
|
$
|
16,574
|
(9)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
256,814
|
|
Executive Vice
|
|
|
2007
|
|
|
$
|
231,000
|
|
|
$
|
5,000
|
|
|
|
|
|
|
|
|
|
|
$
|
21,794
|
(3)(6)
|
|
$
|
257,794
|
|
President & Chief Scientific Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pamela G. Boone
|
|
|
2008
|
|
|
$
|
232,000
|
|
|
$
|
18,920
|
(9)
|
|
$
|
15,000
|
(4)
|
|
$
|
|
|
|
|
|
|
|
$
|
265,920
|
|
Executive Vice
|
|
|
2007
|
|
|
$
|
200,000
|
|
|
$
|
5,000
|
|
|
$
|
7,000
|
(4)
|
|
$
|
7,518
|
(5)
|
|
$
|
12,994
|
(6)
|
|
$
|
232,512
|
|
President & Chief Financial Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dave Dallam(7)
|
|
|
2008
|
|
|
$
|
148,289
|
|
|
$
|
9,534
|
(9)
|
|
$
|
1,500
|
(8)
|
|
|
|
|
|
|
|
|
|
$
|
159,322
|
|
Executive Vice President of Sales & Marketing
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Mr. Scheller resigned as the Companys President,
Chief Executive Officer and Chairman of the Board, effective
July 31, 2008. |
|
(2) |
|
The option holdings of Mr. Scheller include an option to
purchase 15,000 shares of Common Stock granted on
March 30, 2007 at $3.58 per share. The option vested 25% on
June 30, 2007, 25% on September 30, 2007, 25% on
December 30, 2007 and 25% on March 30, 2008. The fair
value of options granted during the fiscal year ended
July 31, 2007 was determined at the date of the grant using
a Black-Scholes options-pricing model using an expected average
risk-free interest rate of 4.0%, an expected average life (in
years) of 5, an expected volatility rate of 79.7% and an
expected dividend yield of 0.0%. |
|
(3) |
|
All other compensation for Dr. Malis includes lease
payments on his automobile. |
|
(4) |
|
The restricted stock holdings of Ms. Boone include
17,437 shares of Common Stock of which 6,387 were granted
on March 7, 2006 at $5.48 per share (vesting on
March 7, 2011) and 11,050 shares were granted on
August 1, 2007 at $3.62 per share (vesting on
August 1, 2012). Dividends will be paid on this restricted
stock if the Company grants dividends to its common stockholders. |
|
(5) |
|
The option holdings of Ms. Boone include an option to
purchase 41,310 shares of Common Stock granted on
May 19, 2005 at $1.09 per share. The option will vest 50%
on May 19, 2009 and 50% on May 19, 2010. The fair
value of options granted during the fiscal year ended
July 31, 2005 was determined at the date of the grant using |
16
|
|
|
|
|
a Black-Scholes options-pricing model using an expected average
risk-free interest rate of 3.0%, an expected average life (in
years) of 5, an expected volatility rate of 0.0% and an expected
dividend yield of 0.0%. |
|
(6) |
|
In fiscal 2007, the Company recorded compensation expense as
well as the tax
gross-up for
bonus trips awarded to Mr. Gampp, Dr. Malis and
Ms. Boone for the accomplishments of their 2006 objectives
as the measurement of these accomplishments could not be
completed until fiscal 2007, as discussed in Compensation
Discussion and Analysis. |
|
(7) |
|
Mr. Dallams employment began on November 11,
2007. |
|
(8) |
|
The restricted stock holdings of Mr. Dallam include
5,792 shares of Common Stock granted on January 31,
2008 at $2.59 per share. The restricted stock will vest on
January 31, 2013. Dividends will be paid on this restricted
stock if the Company grants dividends to its common stockholders. |
|
(9) |
|
Includes Christmas bonus of $5,000 for each of
Mr. Scheller, Mr. Gampp, Dr. Malis and
Ms. Boone, $500 for Mr. Dallam, plus an amount
determined by the accomplishment of objective score as described
in the section Compensation Discussion and Analysis
above. |
2008
Grants of Plan Based Awards Table
The following table sets forth additional information about
plan-based awards granted in the fiscal year ended July 31,
2008:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
All Other
|
|
All Other
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock
|
|
Option
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Awards;
|
|
Awards;
|
|
Exercise
|
|
Grant Date
|
|
|
|
|
|
|
|
|
|
|
Number of
|
|
Number of
|
|
or Base
|
|
Fair Value
|
|
|
|
|
Estimated Future Payouts Under
|
|
Shares of
|
|
Securities
|
|
Price of
|
|
of Stock and
|
|
|
Grant
|
|
Equity Incentive Plan Awards
|
|
Stock or
|
|
Underlying
|
|
Option
|
|
Option
|
Name
|
|
Date
|
|
Threshold
|
|
Target
|
|
Maximum
|
|
Units
|
|
Options
|
|
Awards
|
|
Awards
|
|
Pamela G. Boone
|
|
|
8/1/2007
|
|
|
|
|
|
|
|
11,050
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
40,000
|
|
Dave Dallam
|
|
|
1/31/2008
|
|
|
|
|
|
|
|
5,792
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
15,000
|
|
Narrative
to Summary Compensation Table and Grants of Plan-Based Awards
Table
During fiscal years 2007 and 2008, the terms of employment for
Messrs. Scheller, Gampp and Malis were governed by each of
their employment agreements with the Company entered into
pursuant to the terms of the merger between Synergetics, Inc.
and Valley Forge as described in the Companys Registration
Statement on
Form S-4
filed with the SEC (File
No. 333-125521).
Ms. Boone has also entered an employment agreement, the
terms of which are more fully discussed in the section
EMPLOYMENT AGREEMENTS AND SEVERANCE AGREEMENTS below.
Pursuant to the terms of their agreements,
Mr. Schellers initial base salary was $377,000,
Mr. Gampps initial base salary was $346,000 and
Dr. Malis initial base salary was $230,000; provided
that after the first year of employment, each of their base
salaries was determined by the Compensation Committee, subject
to Board approval, and in no event could be lower than their
respective initial base salaries. In addition, each of them
received such other benefits that the Company provides to its
executive officers, including healthcare, life insurance,
disability and 30 days of paid vacation. Each of
Messrs. Scheller, Gampp and Malis were eligible to receive
an annual bonus as determined in the sole discretion of the
Compensation Committee. The determination of annual bonuses
awarded to Messrs. Scheller, Gampp and Malis is more fully
discussed in the section Compensation Discussion and
Analysis. Messrs. Gampps and Malis
employment agreements expired on September 21, 2008
according to their terms. The negative covenant provisions in
these agreements survive.
Pursuant to the terms of their agreements, Ms. Boone
received 11,050 shares of restricted stock as part of her
annual compensation and Mr. Dallam received
5,792 shares of restricted stock as part of his quarterly
compensation.
17
2008
Outstanding Equity Awards at Fiscal Year-End
The following table sets forth information on outstanding
options and stock awards held by the named executive officers as
of July 31, 2008:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Option Awards
|
|
|
Stock Awards
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Incentive
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Plan
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Awards:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity
|
|
|
Market
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Incentive
|
|
|
or Payout
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Plan
|
|
|
Value of
|
|
|
|
|
|
|
|
|
|
Equity
|
|
|
|
|
|
|
|
|
|
|
|
Market
|
|
|
Awards:
|
|
|
Unearned
|
|
|
|
|
|
|
|
|
|
Incentive
|
|
|
|
|
|
|
|
|
|
|
|
Value of
|
|
|
Number
|
|
|
Shares,
|
|
|
|
|
|
|
|
|
|
Plan Awards:
|
|
|
|
|
|
|
|
|
|
|
|
Shares or
|
|
|
of Unearned
|
|
|
Units or
|
|
|
|
Number of
|
|
|
Number of
|
|
|
Number
|
|
|
|
|
|
|
|
|
Number of
|
|
|
Units of
|
|
|
Shares,
|
|
|
Other
|
|
|
|
Securities
|
|
|
Securities
|
|
|
of Securities
|
|
|
|
|
|
|
|
|
Shares or
|
|
|
Stock
|
|
|
Units or
|
|
|
Rights
|
|
|
|
Underlying
|
|
|
Underlying
|
|
|
Underlying
|
|
|
|
|
|
|
|
|
Units of
|
|
|
That
|
|
|
Other
|
|
|
That
|
|
|
|
Unexercised
|
|
|
Unexercised
|
|
|
Unexercised
|
|
|
Option
|
|
|
|
|
|
Stock That
|
|
|
Have
|
|
|
Rights
|
|
|
Have
|
|
|
|
Options
|
|
|
Options
|
|
|
Unearned
|
|
|
Exercise
|
|
|
Option
|
|
|
Have Not
|
|
|
Not
|
|
|
That Have
|
|
|
Not
|
|
|
|
(#)
|
|
|
(#)
|
|
|
Options
|
|
|
Price
|
|
|
Expiration
|
|
|
Vested
|
|
|
Vested
|
|
|
Not Vested
|
|
|
Vested
|
|
Name
|
|
Exercisable
|
|
|
Unexercisable
|
|
|
(#)
|
|
|
($)
|
|
|
Date
|
|
|
(#)
|
|
|
($)
|
|
|
(#)
|
|
|
($)
|
|
|
Gregg D. Scheller
|
|
|
15,000
|
(1)
|
|
|
|
|
|
|
|
|
|
$
|
3.58
|
|
|
|
July 31, 2010
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Jerry L. Malis
|
|
|
50,000
|
(2)
|
|
|
|
|
|
|
|
|
|
$
|
1.125
|
|
|
|
December 12, 2010
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pamela G. Boone
|
|
|
|
|
|
|
41,310
|
(3)
|
|
|
|
|
|
$
|
1.089
|
|
|
|
May 19, 2015
|
|
|
|
|
|
|
|
|
|
|
|
17,437(4
|
)
|
|
$
|
51,787
|
|
Dave Dallam
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,792(5
|
)
|
|
$
|
17,202
|
|
|
|
|
(1) |
|
The option holdings of Mr. Scheller include an option to
purchase 15,000 shares of Common Stock granted on
March 30, 2007 at an exercise price of $3.58 per share. The
option vested 25% on June 30, 2007, 25% on
September 30, 2007, 25% on December 30, 2007 and 25%
on March 30, 2008. |
|
(2) |
|
The option holdings of Dr. Malis include an option to
purchase 50,000 shares of Common Stock granted on
December 12, 2000 at an exercise price of $1.125 per share.
The option expires on December 12, 2010 and is exercisable
as of July 31, 2006. |
|
(3) |
|
The option holdings of Ms. Boone include an option to
purchase 41,310 shares of Common Stock granted on
May 19, 2005 at an exercise price of $1.09 per share. The
option will vest 50% on May 19, 2009 and 50% on
May 19, 2010. |
|
(4) |
|
The restricted stock holdings of Ms. Boone include
17,437 shares of which 6,387 were granted on March 7,
2006 at $5.48 per share, vesting on March 7, 2011, and
11,050 were granted on August 1, 2007 at $3.62 per share,
vesting on August 1, 2012. Dividends will be paid on this
restricted stock if the Company grants dividends to its common
stockholders. |
|
(5) |
|
The restricted stock holdings of Mr. Dallam include
5,792 shares granted on January 31, 2008 which will
vest 100% on January 31, 2013. Dividends will be paid on
this restricted stock if the Company grants dividends to its
common stockholders. |
Mr. Gampp did not have any options to purchase Synergetics
USA Common Stock nor restricted stock awards as of July 31,
2008.
EMPLOYMENT
AGREEMENTS AND SEVERANCE AGREEMENTS
Ms. Boone entered into three-year employment agreement with
the Company on August 1, 2007. Pursuant to her agreement,
Ms. Boones base salary is $232,000. In addition,
Ms. Boone receives such other benefits that the Company
provides to its executive officers, including healthcare, life
insurance, disability and 30 days of paid vacation.
Ms. Boone is eligible to receive an annual bonus, as may be
determined in the sole discretion of the Compensation Committee
of the Companys Board of Directors.
If Ms. Boone is terminated without cause or within twelve
months following a change of control, or if she resigns for good
reason, she shall be entitled to her base salary and health care
benefits for a
15-month
period following termination. As used in the employment
agreement, cause means (1) the executive
officers conviction of any felony, or conviction for
embezzlement or misappropriation of Company money or other
property; (2) any act of gross negligence in performing the
executive officers duties; (3) the executive
officers willful refusal to execute her duties (other than
for disability); or (4) the executive officers breach
of the non-competition terms contained in
18
her employment agreement. Termination for the events described
in clauses (2) and (3) above will not constitute
termination for cause unless the executive officer
is provided written notice reasonably detailing such occurrence
and is given five business days after receipt of such notice to
cure such event and an opportunity to be heard before the
Companys Board of Directors.
As used in the employment agreement with Ms. Boone, the
term good reason means (1) failure to pay, or a
reduction, by the Company of the executive officers base
salary; (2) the failure or refusal by the Company to
provide the executive officer with the benefits set forth in her
employment agreement; (3) the assignment to the executive
officer of any duties materially inconsistent with the duties
set forth in the employment agreement, which assignment is not
cured within five business days of written notice to the
Company; (4) a requirement imposed by the Company on
Ms. Boone that results in her being based at a location
that is outside a
35-mile
radius from the Companys current corporate offices in
OFallon, Missouri; (5) a change in the executive
officers title; (6) any material breach by the
Company of the employment agreement, which breach is not cured
within five business days after receipt of written notice from
the executive officer; or (7) the termination of the
executive officers employment other than for cause, death
or disability.
Change of control is defined in Ms. Boones employment
agreement to mean a change in the ownership or effective control
of the Company, or a change in the ownership of a substantial
portion of the Company.
The employment agreement for Ms. Boone contains
non-competition covenants, depending on the circumstances of any
termination of employment, and non-solicitation provisions.
Furthermore, Ms. Boone is subject to an agreement that any
products, inventions, discoveries and improvements made by her
during the employment term shall be the property of the Company.
POST-TERMINATION
PAYMENTS
Ms. Boones employment agreement provides for certain
payments to be made to her upon termination of her employment
without cause or her resignation for good reason.
Ms. Boones agreement also states that she shall
receive payments if her employment is terminated within
12 months of a change of control, but that no payments upon
termination or resignation as described above shall be received
upon her breach of the non-competition and non-solicitation
provisions of her employment agreement. Mr. Dallams
letter agreement provides for a severance package of one
years salary in the event there is a change of control.
Furthermore, if any of the named executive officers
employment is terminated upon a change of control, all options
to purchase Common Stock and all restricted stock shall vest.
Assuming that the triggering event for post-termination payments
occurred on the last business day of the Companys fiscal
2008, the named executive officers would receive the following
payments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock
|
|
|
Named Executive Officer
|
|
Salary
|
|
Compensation
|
|
Total
|
|
Pamela G. Boone(1)
|
|
$
|
304,500
|
|
|
$
|
129,450
|
|
|
$
|
433,950
|
|
Dave Dallam(1)
|
|
$
|
223,600
|
|
|
$
|
17,202
|
|
|
$
|
240,802
|
|
|
|
|
(1) |
|
The salary calculations for Ms. Boone and Mr. Dallam
include 15 months of salary and 12 months of salary,
respectively, as these are the required payments per
Ms. Boones employment contract and
Mr. Dallams letter agreement. In addition,
Ms. Boone would receive 15,263 shares of restricted
stock which had not been awarded as of July 31, 2008. |
CERTAIN
RELATIONSHIPS AND RELATED TRANSACTIONS
Since the late 1960s, the late Dr. Leonard Malis, one
of Valley Forges former directors, on an individual basis
has been a party to consulting and other agreements with
Codman & Shurtleff, Inc., the Companys principal
customer. Since 1983, Dr. Leonard Malis has been a party to
an agreement with Codman under which Dr. Leonard Malis
received royalty payments for the use of the
Malis®
trademark on certain products sold by Codman to end users,
including products Valley Forge sold to Codman. Dr. Leonard
Malis developed passive hand instruments for Codman with no
pecuniary benefits to Valley Forge. On October 22, 2004,
Valley Forge entered into an option agreement with
Dr. Leonard Malis under which
19
Valley Forge was granted an option to acquire the
Malis®
trademark from Dr. Leonard Malis at any time over a period
of five years.
On October 12, 2005, the Company exercised its option with
respect to the
Malis®
trademark. We paid the estate of Dr. Leonard I. Malis
$159,904 in cash and the remainder in a $3,997,600 promissory
note which will be paid in 25 equal quarterly installments of
$159,904. The Company has made four quarterly payments on this
note during the year ended July 31, 2008. The promissory
note is secured by a security interest in the trademark and our
DualWavetm
patents.
To identify and address any concerns regarding related party
transactions and ensure their proper disclosure, the Company
requires such transactions to be reported in its questionnaires
distributed to directors and officers each year and mandates
that all employees and directors report to a manager, supervisor
or other appropriate personnel all transactions presenting
potential conflicts of interest pursuant to its Code of Business
Conduct & Ethics. It is the policy that the
Companys Audit Committee review and approve all material
related party transactions required to be reported pursuant to
Item 404(a) of
Regulation S-K.
PROPOSAL 2
APPROVAL OF AMENDMENT NO. 1 TO THE AMENDED AND RESTATED
2005 NON-EMPLOYEE DIRECTORS STOCK OPTION PLAN
On October 7, 2008, the Board of Directors adopted, subject
to stockholder approval, Amendment No. 1 (Amendment
No. 1) to the Amended and Restated Synergetics USA,
Inc. 2005 Non-Employee Directors Stock Option Plan (the
2005 Directors Plan). If adopted by the
stockholders, Amendment No. 1 would increase the number of
shares authorized for issuance under the
2005 Directors Plan from 200,000 to 400,000.
The 2005 Directors Plan enhances the flexibility of
our Board of Directors in granting stock options to the
non-employee directors of the Board and ensures that the Company
can continue to grant stock options to such persons at levels
determined appropriate by the Board based on comparable Company
and other market data. The Company believes that stock options
are a critical component of the compensation package offered to
non-employee directors and are important tools in the
Companys ability to attract and retain talented and
experienced non-employee directors. The Company further believes
that the granting of stock options to non-employee directors
links the personal interests of such non-employee directors with
the Companys stockholders.
A copy of Amendment No. 1 is attached as Appendix A to
this proxy statement. The following summary of the material
terms of the 2005 Directors Plan, as amended by
Amendment No. 1, is qualified in its entirety by reference
to the full text of the 2005 Directors Plan, as
amended.
Administration
The 2005 Directors Plan is administered by the Board
of Directors. Except for automatic grants of stock options, the
Board, or a committee appointed by the Board, has the exclusive
authority and sole discretion to administer the
2005 Directors Plan, including the power to determine
eligibility, the types and sizes of awards, the price and timing
of awards and the acceleration or waiver of any vesting
restriction, subject to the limitations set forth in the
2005 Directors Plan.
Eligibility
Persons eligible to participate in the 2005 Directors
Plan include all directors of the Company who are not either
employees of the Company or any of its subsidiaries or members
of the immediate family of an employee or director of the
Company or any of its subsidiaries. As of the record date, there
were four non-employee directors of the Company.
Number of
Shares Subject to the 2005 Directors Plan
The maximum number of shares of the Companys Common Stock
that may be issued under the 2005 Directors Plan is
currently 200,000. If Amendment No. 1 is approved by the
stockholders, the maximum number of
20
shares authorized for issuance under the
2005 Directors Plan will be increased to 400,000. As
of November 10, 2008, the market value of a share of the
Companys Common Stock was $1.20.
Stock
Option Grants
Under the 2005 Directors Plan, a non-employee
director is entitled to two types of automatic grants, as well
as discretionary grants by the Board of Directors or a committee
appointed by the Board.
The first type of automatic grant is an initial option grant to
the Companys non-employee directors the next business day
after their initial election or appointment to the
Companys Board of Directors. These initial option grants
are for 10,000 shares, have a term of ten years and are
immediately vested and exercisable with an exercise price equal
to the fair market value of a share of the Companys Common
Stock on the date of grant. The unexercised options will be
exercisable for two years after a non-employee director ceases
to be a director.
The second type of automatic option grant is the annual option
grant to each non-employee director on the first business day
following the annual meeting of the Companys stockholders
at which the non-employee director is re-elected as a director
of the Company. The annual meeting option grants are for
10,000 shares, have a term of ten years and vest
pro-ratably over the next twelve months. The exercise price is
equal to the fair market value of a share of the Companys
Common Stock on the date of grant. The unexercised options will
be exercisable for two years after a non-employee ceases to be a
director with certain exceptions.
The 2005 Directors Plan also provides for the
discretionary grant of options to non-employee directors.
The grant of an option to a non-employee director under the
2005 Directors Plan will not produce any taxable
income to the director, and the Company will not be entitled to
a deduction at that time. On the date the option is exercised,
the director will recognize ordinary income equal to the
difference between the fair market value of the Companys
Common Stock on the date of exercise and the exercise price. The
Company will be entitled to a corresponding deduction in the
same amount and in the same year in which the director
recognizes income.
Transferability
Stock options granted pursuant to the 2005 Directors
Plan are transferable by will or the laws of descent and
distribution, or pursuant to a qualified domestic relations
order. The Board may, in its discretion, provide that stock
options granted to a non-employee director may be transferred,
in whole or in part, to one or more transferees provided that
(i) any such transfer must be without consideration;
(ii) each transferee must be a member of the non-employee
directors immediate family or a trust, family limited
partnership or other estate planning vehicle established for the
exclusive benefit of one or more members of the non-employee
directors family; and (iii) such transfer must be
specifically approved by the Board.
Amendment
and Termination
The Board of Directors may terminate, amend or modify the
2005 Directors Plan at any time. However, stockholder
approval is required for any amendment to the extent necessary
or desirable to comply with any applicable law, regulation or
stock exchange rule.
Unless otherwise terminated earlier by the Board of Directors,
the 2005 Directors Plan shall terminate on
May 30, 2015, ten years after the effective date.
New Plan
Benefits
Under the terms of the 2005 Directors Plan, each of
the non-employee directors will receive an automatic grant of an
option to purchase 10,000 shares of Common Stock on the
first business day following the 2008 Annual
21
Meeting. The following table discloses the annual grants of
options to purchase Common Stock that will be received by the
non-employee directors.
Amended and Restated Synergetics USA, Inc. 2005 Non-Employee
Directors Stock Option Plan
|
|
|
|
|
|
|
|
|
|
|
Dollar Value
|
|
|
Number of
|
|
Name and Position
|
|
($)
|
|
|
Units
|
|
|
Pamela G. Boone, Executive Vice President and Chief Financial
Officer
|
|
|
0
|
|
|
|
0
|
|
Kurt Gampp, Jr., Executive Vice President and Chief Operating
Officer
|
|
|
0
|
|
|
|
0
|
|
Jerry Malis, Executive Vice President and Chief Scientific
Officer
|
|
|
0
|
|
|
|
0
|
|
Dave Dallam, Executive Vice President of Sales and Marketing
|
|
|
0
|
|
|
|
0
|
|
Gregg D. Scheller(1)
|
|
|
0
|
|
|
|
0
|
|
Executive Group
|
|
|
0
|
|
|
|
0
|
|
Non-Executive Director Group(2)
|
|
|
0
|
|
|
|
40,000
|
|
Non-Executive Officer Employee Group
|
|
|
0
|
|
|
|
0
|
|
|
|
|
(1) |
|
Mr. Scheller resigned as the Companys President,
Chief Executive Officer and Chairman of the Board of Directors
on July 31, 2008. |
|
(2) |
|
Includes Messrs. Cardinale, Dick and Guarch and
Ms. Hinshaw. |
None of the current director nominees, no Company employees and
no associate of a current director, executive officer or nominee
will receive options pursuant to the 2005 Directors
Plan, as amended by Amendment No. 1 if approved by
stockholders, as only non-employee directors are eligible to
receive option grants pursuant to the 2005 Directors
Plan.
Equity
Compensation Plan Information
The following table summarizes information regarding our equity
compensation plans in effect as of July 31, 2008.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of
|
|
|
|
|
|
|
|
|
|
Securities
|
|
|
|
Number of
|
|
|
|
|
|
Remaining Available
|
|
|
|
Securities to be
|
|
|
|
|
|
for Issuance Under
|
|
|
|
Issued Upon
|
|
|
Weighted-Average
|
|
|
Equity Compensation
|
|
|
|
Exercise of
|
|
|
Exercise Price of
|
|
|
Plans (Excluding
|
|
|
|
Outstanding
|
|
|
Outstanding
|
|
|
Securities
|
|
|
|
Options, Warrants
|
|
|
Options, Warrants
|
|
|
Reflected in Column
|
|
|
|
and Rights
|
|
|
and Rights
|
|
|
(a))
|
|
Plan Category
|
|
(a)
|
|
|
(b)
|
|
|
(c)
|
|
|
Equity compensation plans approved by security holdings
|
|
|
436,735
|
|
|
$
|
2.23
|
|
|
|
1,072,480
|
|
Equity compensation plans not approved by security holders
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
436,735
|
|
|
$
|
2.23
|
|
|
|
1,072,480
|
|
THE BOARD
OF DIRECTORS RECOMMENDS A VOTE FOR APPROVAL OF
AMENDMENT
NO. 1 TO THE 2005 DIRECTORS PLAN
22
PROPOSAL 3
RATIFICATION OF THE APPOINTMENT OF THE COMPANYS
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
On January 10, 2007, the Audit Committee of the Company
terminated the engagement of McGladrey & Pullen, LLP
(McGladrey) as the Companys independent
registered public accounting firm. McGladreys reports on
the Companys financial statements for the fiscal year
ended July 31, 2006 did not contain an adverse opinion or a
disclaimer of opinion, and were not qualified or modified as to
uncertainty, audit scope or accounting principles. Furthermore,
no disagreements with McGladrey on any matter of accounting
principles or practices, financial statement disclosure or
auditing scope or procedures, which disagreements, if not
resolved to the satisfaction of McGladrey, would have caused it
to make reference to the subject matter of the disagreement in
connection with its reports on the Companys financial
statements for such periods. None of the reportable events
described in Item 304(a)(1)(v) of
Regulation S-K
occurred during McGladreys engagement.
Effective January 9, 2007, the Audit Committee appointed
UHY as the Companys new independent registered public
accounting firm. Prior to the aforementioned engagement, the
Company did not consult with UHY with respect to any of the
matters or reportable events set forth in Item 304(a)(2)(i)
and (ii) of
Regulation S-K.
The firm of UHY acts as our principal independent registered
public accounting firm. Through and as of October 14, 2008,
UHY had a continuing relationship with UHY Advisors, Inc.
(Advisors) from which it leased auditing staff who
were full-time, permanent employees of Advisors and through
which UHYs partners provide non-audit services. UHY has
only a few full-time employees. Therefore, few, if any, of the
audit services performed were provided by permanent, full-time
employees of UHY. UHY manages and supervises the audit services
and audit staff, and is exclusively responsible for the opinion
rendered in connection with its examination.
The following table shows fees billed for professional services
rendered by UHY for fiscal 2007 and fiscal 2008:
|
|
|
|
|
|
|
|
|
|
|
Fiscal Year Ended
|
|
|
Fiscal Year Ended
|
|
|
|
July 31, 2008
|
|
|
July 31, 2007
|
|
|
Audit Fees(1)
|
|
$
|
282,206
|
|
|
$
|
280,000
|
|
Audit-Related Fees
|
|
|
10,150
|
|
|
|
|
|
Tax Fees(2)
|
|
|
|
|
|
|
|
|
All Other Fees
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
292,356
|
|
|
$
|
280,000
|
|
|
|
|
(1) |
|
Audit Fees for the fiscal years ended July 31, 2008 and
2007 include services for the audit of the consolidated
financial statements, report on managements assessment of
the Companys internal control over financial reporting,
the review of the quarterly financial statements and
consultation concerning financial accounting and reporting
standards. |
|
(2) |
|
Tax Fees are comprised of fees relating to income tax matters,
planning and advice. |
Pursuant to the Audit Committees charter, all audit and
permissible non-audit services provided by the independent
registered public accounting firm must be pre-approved. These
services may include audit services, audit-related services, tax
services and other services. Pre-approval is generally provided
for up to one year and any pre-approval is detailed as to the
particular service or category of service. The independent
registered public accounting firm and management are required to
periodically report to the Audit Committee regarding the extent
of services provided by the independent registered public
accounting firm in accordance with the policies set forth in the
Audit Committee charter. Consistent with the Audit
Committees policy, all audit and permissible non-audit
services provided by McGladrey & Pullen, LLP and UHY
during the fiscal year ended July 31, 2007, and UHY
exclusively for the fiscal year ended July 31, 2008, were
pre-approved by the Audit Committee.
23
In considering the nature of the services provided by the
independent registered public accounting firm, for the fiscal
year ended July 31, 2008 the Audit Committee determined
that such services are compatible with the provision of
independent audit services. The Audit Committee discussed these
services with the independent registered public accounting firm
and management for the fiscal year ended July 31, 2008 to
determine that they are permitted under the rules and
regulations concerning auditors independence promulgated
by the SEC to implement the Sarbanes-Oxley Act of 2002, as well
as rules of the American Institute of Certified Public
Accountants.
UHY acted as the Companys independent registered public
accounting firm for the 2008 fiscal year. The Audit Committee
selected UHY to act as the Companys independent registered
public accounting firm for the 2009 fiscal year. UHY
representatives are expected to attend the Annual Meeting. They
will have an opportunity to make a statement if they desire to
do so and will be available to respond to appropriate questions.
The Company is asking its stockholders to ratify the selection
of UHY as the Companys independent registered public
accounting firm. Although ratification is not required by our
bylaws or otherwise, the Board is submitting the selection of
UHY to our stockholders for ratification as a matter of good
corporate practice. If the selection is not ratified, the Audit
Committee will consider whether it is appropriate to select
another independent registered public accounting firm. Even if
the selection is ratified, the Audit Committee in its discretion
may select a different independent registered public accounting
firm at any time during the fiscal year if it determines that
such a change would be in the best interests of the Company and
its stockholders.
THE BOARD
OF DIRECTORS RECOMMENDS A VOTE FOR RATIFICATION OF THE
APPOINTMENT OF THE COMPANYS INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM
REPORT OF
THE AUDIT COMMITTEE
The Audit Committee (the Committee) oversees the
Companys financial reporting process on behalf of the
Board of Directors. Management has the primary responsibility
for the financial statements and the reporting process,
including internal control systems. The Companys
independent registered public accounting firm is responsible for
expressing an opinion on the conformity of the Companys
audited financial statements with U.S. generally accepted
accounting principles and reporting on managements
assessment of the Companys internal control over financial
reporting.
In fulfilling its oversight responsibilities, the Committee
reviewed and discussed with management the audited financial
statements in the Annual Report on
Form 10-K
for the year ended July 31, 2008, including a discussion of
the accounting principles, the reasonableness of significant
judgments and the clarity of disclosures in the financial
statements.
In addition, the Committee discussed with the independent
registered public accounting firm their judgments as to the
Companys accounting principles and such other matters as
are required to be discussed with the Committee under standards
of the Public Company Accounting Oversight Board (United States)
and SAS 61 (Codification of Statements on Auditing Standards).
The Committee met with the independent registered public
accounting firm, with and without management present, to discuss
the results of their examinations, their evaluations of the
Companys internal control over financial reporting, and
the overall quality of the Companys financial reporting.
The Committee has received from the independent registered
public accounting firm a formal written statement describing all
relationships between the firm and the Company that might bear
on the independence of the independent registered public
accounting firm consistent with Independence Standards Board
Standard No. 1 (Independence Discussions with Audit
Committees), discussed with the independent registered public
accounting firm any relationships that may impact their
objectivity and independence and satisfied itself as to their
independence.
24
In reliance on the reviews and discussions referred to above,
the Committee recommended to the Board of Directors (and the
Board has approved) that the audited financial statements be
included in the Annual Report on
Form 10-K
for the year ended July 31, 2008, filed with the SEC.
Submitted by the Audit Committee of
the Board of Directors.
Juanita H. Hinshaw (Chairperson)
Lawrence C. Cardinale
Robert H. Dick
OTHER
MATTERS
Management does not know of any other business that may be
considered at the Annual Meeting. However, if any matters other
than those referred to above should properly come before the
Annual Meeting, it is the intention of the persons named in the
accompanying form of proxy to vote the proxies held by them in
accordance with their best judgment.
The Company will bear the costs of its solicitation of proxies.
In addition to the use of the mails, proxies may be solicited by
electronic mail, personal interview, telephone, telegram and
telefax by the directors, officers and employees of the Company.
Arrangements will also be made with brokerage houses and other
custodians, nominees and fiduciaries for the forwarding of
solicitation material to the beneficial owners of stock held of
record by such persons, and the Company may reimburse such
custodians, nominees and fiduciaries for reasonable
out-of-pocket expenses incurred by them in connection therewith.
FORM 10-K
Along with mailing the proxy materials, we have included a copy
of our Annual Report on
Form 10-K
for the fiscal year ended July 31, 2008. We will provide
stockholders with additional copies of our Annual Report on
Form 10-K
for the fiscal year ended July 31, 2008, without charge,
upon written request to Pamela G. Boone, Secretary, Synergetics
USA, Inc., 3845 Corporate Centre Drive, OFallon, Missouri,
63368.
HOUSEHOLDING
OF PROXY MATERIALS
The SEC has adopted rules that permit companies and
intermediaries (e.g. brokers) to satisfy the delivery
requirements for proxy statements with respect to two or more
stockholders sharing the same address by delivering a single
proxy statement addressed to those stockholders. This process,
which is commonly referred to as householding,
potentially means extra convenience for stockholders and cost
savings for companies.
A number of brokers with accountholders who are stockholders
will be householding our proxy materials. As indicated in the
notice previously provided by these brokers to stockholders, a
single proxy statement will be delivered to multiple
stockholders sharing an address unless contrary instructions
have been received from an affected stockholder. Once you have
received notice from your broker or us that they will be
householding communications to your address, householding will
continue until you are notified otherwise.
Stockholders who currently receive multiple copies of the proxy
statement at their address and would like to request
householding of their communications should contact their broker
or, if a stockholder is a direct holder of shares of our Common
Stock, they should submit a written request to our transfer
agent, American Stock Transfer & Trust Company,
6201
15th Avenue,
Brooklyn, New York, 11219. To delist yourself from
householding in the future you may write the Company at 3845
Corporate Centre Drive, OFallon, Missouri, 63368,
Attention: Pamela G. Boone. Upon request, we will deliver
promptly a separate copy of the proxy statement.
25
STOCKHOLDER
PROPOSALS FOR 2009 ANNUAL MEETING OF STOCKHOLDERS
Stockholder proposals submitted for inclusion in the proxy
statement and form of proxy for the 2009 Annual Meeting of
Stockholders must be received at the corporate offices of the
Company, addressed to the attention of Ms. Pamela G. Boone,
Secretary, Synergetics USA, Inc. no later than July 20,
2009. The proposals must comply with the rules of the SEC
relating to stockholder proposals. The Companys Bylaws
provide that no business may be brought before an annual meeting
unless specified in the notice of meeting, brought before the
meeting by or at the direction of the Board of Directors, or
otherwise brought by a stockholder who has delivered notice to
the Company (containing certain information specified in the
Bylaws) not less than 60 or more than 90 days before the
anniversary date of the immediately preceding annual meeting of
stockholders. Therefore, for the 2009 Annual Meeting of
Stockholders, such notice must be delivered no earlier than
September 12, 2009 and no later than October 12, 2009.
A copy of the full text of these Bylaw provisions may be
obtained by writing to the Secretary at the address indicated
above.
By Order of the Board of Directors,
PAMELA G. BOONE
Secretary
November 17, 2008
26
APPENDIX A
AMENDMENT
NO. 1 TO AMENDED AND RESTATED 2005 SYNERGETICS USA, INC.
NON-EMPLOYEE
DIRECTORS STOCK OPTION PLAN
2005
NON-EMPLOYEE DIRECTORS STOCK OPTION PLAN
RECITALS
WHEREAS, the Board of Directors and stockholders of Synergetics
USA, Inc. (the Company) previously approved the
Amended and Restated Synergetics USA, Inc. 2005 Non-Employee
Directors Stock Option Plan (the Plan);
WHEREAS, the Board of Directors is authorized to administer and
amend the Plan, subject to stockholder approval as may be
required pursuant to rules of the national securities exchange
on which the Companys Common Stock is listed;
WHEREAS, the Board of Directors desires to amend the Plan,
effective as of October 7, 2008.
NOW, THEREFORE, effective as of October 7, 2008, the Plan
is amended as follows:
AMENDMENT
1. Section 3 of the Plan shall be amended to read in
its entirety as follows:
3. Shares and Options. The maximum number
of Shares to be issued pursuant to Options under this Plan shall
be FOUR HUNDRED THOUSAND (400,000) Shares. Shares issued
pursuant to Options granted under this Plan may be issued from
Shares held in the Companys treasury or from authorized
and unissued Shares. If any Option granted under this Plan shall
terminate, expire or be canceled or surrendered as to any
Shares, new Options may thereafter be granted covering such
Shares. Any Option granted hereunder shall be a Nonstautory
Stock Option.
IN WITNESS WHEREOF, this Amendment No. 1 was duly adopted
by the Board of Directors of the Company as of October 7,
2008.
Executed this
7th day
of October, 2008.
|
|
|
|
By:
|
|
Pamela G. Boone, Secretary
A-1
0 SYNERGETICS USA, INC. PROXY SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS OF SYNERGETICS
USA, INC. FOR THE ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON DECEMBER 11, 2008 The
undersigned, having received the notice and accompanying Proxy Statement for said meeting, hereby
appoints Pamela G. Boone and Peter T. Rasche, and each of them, with full power of substitution,
as the undersigneds proxies and attorneys-in-fact to vote at the Annual Meeting of Stockholders
of Synergetics USA, Inc. (the Company) to be held on December 11, 2008 (the Annual Meeting),
or at any adjournment or postponement thereof, all shares of voting stock of the Company which the
undersigned may be entitled to vote. The above proxies are hereby instructed to vote as shown on
the reverse of this card and in their discretion upon such other business as may properly come
before the Annual Meeting or at any adjournment or postponement thereof. (Continued and to be
signed on the reverse side.) 14475 |
ANNUAL MEETING OF STOCKHOLDERS OF SYNERGETICS USA, INC. December 11, 2008 Please sign,
date and mail your proxy card in the envelope provided as soon as possible. Please detach
along perforated line and mail in the envelope provided. 20233000000000001000 6 121108 The Board
of Directors recommends a vote FOR all director nominees, Proposal 2 and Proposal 3. PLEASE
SIGN, DATE AND RETURN PROMPTLY IN THE ENCLOSED ENVELOPE. PLEASE MARK YOUR VOTE IN BLUE OR BLACK INK
AS SHOWN HERE x FOR AGAINST ABSTAIN 1. Election of Directors: 2. Approval of Amendment to Amended
and Restated 2005 Non- Employee Directors Stock Option Plan NOMINEES: 3. Ratification of the
appointment of UHY LLP as independent O Jerry L. Malis FOR ALL NOMINEES O Kurt W. Gampp, Jr.
registered public accounting firm WITHHOLD AUTHORITY FOR ALL NOMINEES This proxy, when
properly executed, will be voted in the manner directed herein by the undersigned stockholder. IF
NO DIRECTION IS MADE, THIS PROXY WILL BE FOR ALL EXCEPT VOTED FOR ALL PROPOSALS. (See
instructions below) PLEASE SIGN, DATE AND RETURN THIS PROXY PROMPTLY USING THE ENCLOSED ENVELOPE
EVEN IF YOU PLAN TO ATTEND THE MEETING. INSTRUCTIONS:To withhold authority to vote for any
individual nominee(s), mark FOR ALL EXCEPT and fill in the circle next to each nominee you wish
to withhold, as shown here: MARK X HERE IF YOU PLAN TO ATTEND THE MEETING. To change the
address on your account, please check the box at right and indicate your new address in the
address space above. Please note that changes to the registered name(s) on the account may not be
submitted via this method. Signature of Stockholder Date: Signature of Stockholder Date:
Note: Please sign exactly as your name or names appear on this Proxy. When shares are held jointly,
each holder should sign. When signing as executor, administrator, attorney, trustee or guardian,
please give full title as such. If the signer is a corporation, please sign full corporate name by
duly authorized officer, giving full title as such. If signer is a partnership, please sign in
partnership name by authorized person. |